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Abstract
Background: MicroRNAs (miRNAs), some of which function as oncogenes or tumor suppressor genes,
are involved in carcinogenesis via regulating cell proliferation and/or cell death. MicroRNA miR-34 was
recently found to be a direct target of p53, functioning downstream of the p53 pathway as a tumor
suppressor. miR-34 targets Notch, HMGA2, and Bcl-2, genes involved in the self-renewal and survival of
cancer stem cells. The role of miR-34 in gastric cancer has not been reported previously. In this study, we
examined the effects of miR-34 restoration on p53-mutant human gastric cancer cells and potential target
gene expression.
Methods: Human gastric cancer cells were transfected with miR-34 mimics or infected with the lentiviral
miR-34-MIF expression system, and validated by miR-34 reporter assay using Bcl-2 3'UTR reporter.
Potential target gene expression was assessed by Western blot for proteins, and by quantitative real-time
RT-PCR for mRNAs. The effects of miR-34 restoration were assessed by cell growth assay, cell cycle
analysis, caspase-3 activation, and cytotoxicity assay, as well as by tumorsphere formation and growth.
Results: Human gastric cancer Kato III cells with miR-34 restoration reduced the expression of target
genes Bcl-2, Notch, and HMGA2. Bcl-2 3'UTR reporter assay showed that the transfected miR-34s were
functional and confirmed that Bcl-2 is a direct target of miR-34. Restoration of miR-34 chemosensitized
Kato III cells with a high level of Bcl-2, but not MKN-45 cells with a low level of Bcl-2. miR-34 impaired
cell growth, accumulated the cells in G1 phase, increased caspase-3 activation, and, more significantly,
inhibited tumorsphere formation and growth.
Conclusion: Our results demonstrate that in p53-deficient human gastric cancer cells, restoration of
functional miR-34 inhibits cell growth and induces chemosensitization and apoptosis, indicating that miR-
34 may restore p53 function. Restoration of miR-34 inhibits tumorsphere formation and growth, which is
reported to be correlated to the self-renewal of cancer stem cells. The mechanism of miR-34-mediated
suppression of self-renewal appears to be related to the direct modulation of downstream targets Bcl-2,
Notch, and HMGA2, indicating that miR-34 may be involved in gastric cancer stem cell self-renewal/
differentiation decision-making. Our study suggests that restoration of the tumor suppressor miR-34 may
provide a novel molecular therapy for p53-mutant gastric cancer.
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MicroRNAs (miRNAs) are a conserved class of non-coding
20–22 nt small RNAs that regulate gene expression by
binding to mRNA, leading to mRNA degradation or inhi-
bition [1]. miRNAs regulate a variety of biological proc-
esses, including developmental timing, signal
transduction, tissue differentiation and maintenance, dis-
ease, and carcinogenesis [1]. Emerging evidence demon-
strates that miRNAs also play an essential role in stem cell
self-renewal and differentiation by negatively regulating
the expression of certain key genes in stem cells [1]. One
study has shown that MicroRNA-21 knockdown disrupts
glioma growth in vivo and displays synergistic cytotoxicity
with neural precursor cell delivered S-TRAIL in human gli-
omas [2]. Another recent study shows that miRNA Let-7
regulates self renewal of breast cancer stem cells [3]. Other
miRNAs, such as miR-15 and miR-16, have been reported
to be able to downregulate Bcl-2, a proto-oncogene over-
expressed in many type of cancers, leading to a prevention
of apoptosis [4,5]. It has been shown that this obstacle to
apoptosis due to overexpression of Bcl-2 results in an
increased number of stem cells in vivo [6]. This suggests
that apoptosis plays a role in regulating the microenviron-
ments of stem cells [7]. Therefore, the Bcl-2 signaling
pathway is necessary for the survival of stem cells, espe-
cially cancer stem cells, because of the overexpression of
Bcl-2 in cancer cells.
Recently, miRNA miR-34 was identified as a p53 target
and a potential tumor suppressor [4,8-12]. Over 50% of
human cancers have mutant p53 and the expression of
miR-34a, b, c appears to be correlated with p53 [10,12].
Bommer et al. reported that the abundance of the three-
member miRNA34 family is directly regulated by p53 in
cell lines and tissues, and the Bcl-2 protein is regulated
directly by miR-34 [10]. The expression of miR-34 is dra-
matically reduced in 6 of 14 (43%) non-small cell lung
cancers (NSCLC) and the restoration of miR-34 expres-
sion inhibits growth of NSCLC cells [10]. He et al.
reported that ectopic expression of miR-34 induces cell
cycle arrest in both primary and tumor-derived cell lines,
which is consistent with the observed ability of miR-34 to
downregulate a program of genes promoting cell cycle
progression [12]. miR-34a has been reported to be
involved in p53-mediated apoptosis in colon cancer and
pancreatic cancer [8,9]. Tazawa et al. provided evidence
that miR-34a induced senescence-like growth arrest in
human colon cancer [13]. Taken together, these published
studies establish that miR-34 is a new tumor suppressor
functioning downstream of the p53 pathway, and provide
impetus to explore the functional restoration of miR-34 as
a novel therapy for cancers lacking p53 signalling.
It has been reported that miR-34 targets Notch, HMGA2,
and Bcl-2, genes involved in the self-renewal and survival
of cancer stem cells [10,12,14]. Delineating the role of
miR-34 in regulation of cell growth and tumor progres-
sion, as well as its potential relationship to cancer stem
cells, will help us better understand the p53 tumor sup-
pressor signalling network, facilitate our research in car-
cinogenesis and cancer therapy, and serve as a basis for
our exploration of novel strategies in cancer diagnosis,
treatment, and prevention. Thus far, there is limited study
on miRNA and gastric cancer; the link between p53 down-
stream target miR-34 and gastric cancer has not been
established; and the role of miR-34 in gastric cancer
remains to be investigated. In the current study, we exam-
ined the effects of functional restoration of miR-34 by
miR-34 mimics and lentiviral miR-34a on human gastric
cancer cells, and the effect of miR-34 on tumorsphere for-
mation and growth of p53-mutant gastric cancer cells.
Methods
Cell culture and reagents
Human gastric cancer cell lines Kato III, AGS, N87,
MKN45, and normal human lung fibroblast cell line WI-
38 were purchased from American Type Culture Collec-
tion and cultured in DMEM (HyClone, Logan, UT), sup-
plemented with 10% fetal bovine serum (FBS; HyClone,
Logan, UT). miRNA miR-34a, b, c mimics, antagonists,
and negative control miRNA mimic (NC mimic) were
obtained from Dharmacon (Chicago, IL) with the
sequences for hsa-miR-34a: 5'-uggcagugucuuagcugguugu-3';
hsa-miR-34b: 5'-caaucacuaacuccacugccau-3'; hsa-miR-34c:
5'-aggcaguguaguuagcugauugc-3'. Bcl-2 3'UTR luciferase
reporter plasmid or its mutant were kindly provided by
Dr. Eric Fearon of the University of Michigan [10].
miR-34 mimic transfection
Gastric cancer cells were transfected 24 hours after being
seeded in 6-well plates. miRNA mimics (100 pmol) in
200 μl of serum-free, antibiotic-free, medium were mixed
with 5 μl of Lipofectamine 2000 transfection reagent (Inv-
itrogen, Carlsbad, CA) dissolved in 200 μl of the same
medium and allowed to stand at room temperature for 20
min. The resulting 400 μl transfection solutions were then
added to each well containing 1.6 ml of medium. Six
hours later, the cultures were replaced with 2 ml fresh
medium supplemented with 10% FBS and antibiotics. For
Western blot, cells were collected after an additional 48
hours.
Lentiviral miR-34a infection and stable cells
The feline immunodeficiency virus (FIV) lentiviral system
expressing miR-34a (miR-34a-MIF) or vector control
(MIF), as well as their lentiviral packaging system, were
purchased from System Biosciences (SBI, Mountain View,
CA). Gastric cancer cells were infected with the FIV lenti-
viral system expressing miR-34a (miR-34a-MIF) or vector
control (MIF), according to the manufacturer's instruc-Page 2 of 12
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tion (Zeocin 50 μg/mL, Invitrogen).
miR-34 Bcl-2 3'UTR luciferase reporter assay
Kato III cells were transfected in 6-well plates with 2 ug of
Bcl-2 3'UTR luciferase reporter plasmid or its mutant, and
2 ug of the control β-galactosidase plasmid per well, using
Lipofectamine 2000 (Invitrogen). Cells in each well were
also co-transfected with 100 pmol of each miR-34 mimics
or NC mimic as indicated, using Lipofectamine 2000.
Luciferase assays were performed 24 hrs after transfection
using Bright-Glo Luciferase Assay System (Promega).
Luciferase activity was normalized relative to β-galactosi-
dase activity detected by the β-galactosidase Assay System
(Promega). In each case, Mutant Bcl-2 3'UTR indicates the
introduction of alterations into the seed complementary
sites of Bcl-2 3'UTR [10]. Luciferase activity was normal-
ized relative to β-gal activity (Promega).
Western blot analysis
To determine the levels of protein expression, cells were
harvested and lysed in a RIPA lysis buffer (50 mM Tris-
HCl, pH 8.0, 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.25%
Sodium deoxycholate and 1 mM EDTA) with freshly
added protease inhibitor cocktail (Roche) for 15 min on
ice, then centrifuged at 13,000 rpm for 10 min. Whole cell
extract was measured for total protein concentration using
Bradford reagent (Bio-Rad, Hercules, CA), and proteins
were resolved by SDS-PAGE (Bio-Rad). After electro-
phoresis, the proteins were electrotransferred to nitrocel-
lulose membranes (Bio-Rad), blocked with 5% skimmed
milk, probed with the relevant primary antibody followed
by HRP (horseradish peroxidase) conjugated secondary
antibody (Pierce, Rockford, IL), and detected with the
SuperSignal West Pico chemiluminescence substrate
(Pierce). Intensity of the desired bands was analyzed using
TotalLab software (Nonlinear Dynamics, Durham, NC).
Quantitative real-time PCR (qRT-PCR)
Quantitative real-time PCR was performed to determine
the expression levels of potential miR-34 target genes. 24
hours after miR-34 mimic transfection of Kato III cells
(100 pmol per well in 6-well plates), potential target
genes' mRNA levels were measured by qRT-PCR with Taq-
Man SYBR Green PCR System (Applied Biosystems).
Briefly, total RNA was extracted from the transfected cells
using TRIZOL (Invitrogen) according to the manufac-
turer's instructions. Reverse transcription was performed
using a TaqMan Reverse Transcription Kit (Applied Bio-
systems). For qRT-PCR, 1 μl of gene primers with SYBR
Green (Applied Biosystems) in 20 μl of reaction volume
was applied. Primers were designed as: Bcl-2, forward, 5'-
CAT GCT GGG GCC GTA CAG-3', reverse, 5'-GAA CCG
GCA CCT GCA CAC-3'; HMGA2, forward, 5'-TTT GTA
ATC CCT TCA CAG TCC-3', reverse, 5'-TTT CTC ACC CGC
CCA C-3'; Notch1, forward, 5'-ATC CAG AGG CAA ACG
GAG-3', reverse, 5'-CAC ATG GCA ACA TCT AAC CC-3';
Notch2, forward, 5'-GGA CCC TGT CAT ACC CTC TT-3',
reverse, 5'-CAT GCT TAC GCT TTC GTT TT-3'; Notch3,
forward, 5'-TGA TCG GCT CGG TAG TAA TG-3', reverse,
5'-CAA CGC TCC CAG GTA GTC A-3'; Notch4, forward,
5'-TGC GAG GAA GAT ACG GAG TG-3', reverse, 5'-CGG
GAT CGG AAT GTT GG-3'; β-actin, forward, 5'-ATG CAG
AAG GAG ATC ACT GC-3', reverse, 5'-TCA TAG TCC GCC
TAG AAG CA-3'. All reactions with TaqMan Universal PCR
Master Mix (Applied Biosystems) were performed on the
Mastercycler realplex 2 system (Eppendorf, Westbury, NY).
Target gene mRNA levels were normalized to Actin mRNA
according to the following formula: [2^ - (CTtarget - CTActin)]
× 100%, where CT is the threshold cycle. Fold increase was
calculated by dividing the normalized target gene expres-
sion of the treated sample with that of the untreated con-
trol, with the value from the NC mimic set as 1.
Cell cycle analysis
For cell cycle analysis by flow cytometry, Kato III cells
were transfected with miR-34 mimics or NC mimic in 6-
well plates, trypsinized 24 hours later and washed with
phosphate-buffered saline, and fixed in 70% ethanol on
ice. After centrifugation, cells were stained with 50 μg/ml
propidium iodide and 0.1 μg/ml RNase A, and analyzed
by flow cytometry using a FACStar Plus™. Each histogram
was constructed with data from at least 5,000 events. Data
were analyzed to calculate the percentage of cell popula-
tion in each phase using CellQuest software (Becton Dick-
inson).
Caspase-3 activation assay
Caspase activation of transfected Kato III cells was deter-
mined following the instructions of a Caspase-3 activa-
tion assay kit (BioVision, Mountain View, CA). 24 hours
after transfection, cells were lysed and whole cell lysates
(20 μg) were incubated with 25 μM fluorogenic substrate
DEVD-AFC in a reaction buffer (containing 5 mM DTT) at
37°C for 2 h. Proteolytic release of AFC was monitored at
λex = 405 nm and λem = 500 nm using a fluorescence
microplate reader (BMG LABTECH, Durham, NC). Rela-
tive increase of fluorescence signal was calculated by
dividing the normalized signal in each treated sample
with that of NC mimic as 100.
Cell cytotoxicity assay
For cytotoxicity assay, the water-soluble tetrazolium salt
WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-
5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium
salt] uptake method was employed, using CCK-8 reagent
(Dojindo, Gaithersburg, MD). Briefly, Kato III cells were
transfected with miR-34 mimics or NC mimic for 24 h,
plated in 96-well plates (5,000 cells/well), and treated
with serially diluted chemotherapeutic agents in triplicate.Page 3 of 12
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added and incubated at 37°C for 1–3 h. Optical density
was measured at 450 nm and 650 nm using a microplate
reader (BMG LABTECH). Final absorbance was obtained
by subtracting the absorbance at 450 nm from that at 650
nm, and cell viability (%) was normalized by dividing
final absorbance of treated samples with that of the
untreated control. IC50, the drug concentration that inhib-
its 50% cell growth, was calculated by GraphPad Prism
5.0 (San Diego, CA), as we described previously [15].
Tumorsphere culture
Cells were suspended in serum-free culture medium
DMEM containing 1% N2 supplement, 2% B27 supple-
ment, 1% antibotic-antimycotic (Invitrogen), 20 ng/ml
human FGF-2 (Sigma, Saint Louis, MO), and 100 ng/ml
EGF (Invitrogen), and plated in 24-well ultra-low attach-
ment plates (Corning, Corning, NY) at 2,000 cells per
well. 7–10 days later, plates were analyzed for tumor-
sphere formation and were quantified using an inverted
microscope (Olympus) at 100×, 200×, and 400× magnifi-
cation. For subsequent quantification of cell numbers per
tumorsphere, tumorspheres were collected and filtered
through a 40 um sieve (BD Biosciences, San Jose, CA), and
disassociated with 2.5% trypsin, while the viable cells
were counted with trypan blue exclusion.
Statistical analysis
Data were analyzed with Student's two-tailed t-test or one-
way ANOVA, using GraphPad Prism 5.0 software (Graph-
Pad Prism, San Diego, CA). P < 0.05 was defined as statis-
tically significant.
Results
Expression of miR-34 and target genes in human gastric 
cancer cell lines
We have examined the four human gastric cancer cell
lines, Kato III, AGS, N87, and MKN45, for their expression
levels of Bcl-2 as well as other members of the Bcl-2 family
proteins. As shown in Figure 1, Kato III cells have a high
level of Bcl-2, while AGS and MKN-45 cells have very low
levels of Bcl-2 (undetectable by Western blot). We next
examined these gastric cancer cell lines for the expression
level of miR-34 and target genes using qRT-PCR. Kato III
cells have the lowest levels of both pri-miR34a and
mature miR-34a, and the highest expression levels of tar-
get genes Bcl-2, Notch1, and Notch4 (Figure 2). Since
miR-34 is a downstream target of the p53 pathway and
Bcl-2 is a direct target of miR-34, our data with Kato III are
consistent with the cells' p53-mutant status, i.e., Kato III
has mutant p53, the lowest level of miR-34, and the high-
est level of Bcl-2. Therefore, we focused on this cell line for
the current study of the effect of miR-34 restoration.
Transfection of miR-34 mimics in p53-mutant gastric 
cancer cells
For miR-34 restoration, we transfected the Kato III cells
with miR-34 mimics. As shown in Figure 3, Western blot
analysis revealed that transfection of miR-34 mimics
downregulated target gene Bcl-2 expression at the protein
level, but had no obvious effect on Bcl-xL and Mcl-1
expression, indicating that the Bcl-2 knockdown by miR-
34 mimics was sequence-specific. As a target of miR-34,
Bax was also downregulated by miR-34. Western blot
results were validated by qRT-PCR analysis (Figure 4).
More importantly, other potential miR-34 target genes
were inhibited in addition to Bcl-2. As shown in Figure 4,
Notch1 and HMGA2 were inhibited by all three miR-34a,
b, c mimics, while miR-34b mimic inhibited Notch2 and
4, and miR-34c mimic inhibited Notch1-4. Notch1-2
knockdown by miR-34 mimics has been confirmed by
Western blot (data not shown).
Transfected miR-34s are functional
To evaluate whether the transfected miR-34 mimics were
functional, we carried out the Bcl-2 3'UTR reporter assay
as described by Bommer et al. [10]. KATO3 cells were
transfected with Bcl-2 3'UTR luciferase reporter plasmid
or its mutant, plus the control β-galactosidase plasmid
and 100 pmol of each miR-34 mimic or NC mimic. As
shown in Figure 5, the transfected miR-34 mimics effec-
tively inhibited luciferase reporter gene expression, which
is controlled by Bcl-2 3'UTR in the promoter region. How-
Western blot analysis of the expression of Bcl-2 family pro-tein  in human g str c canc r cell linesFigure 1
Western blot analysis of the expression of Bcl-2 fam-
ily proteins in human gastric cancer cell lines.
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miR-34 root sequence abolished this effect, indicating
that the observed reporter activity is miR-34 sequence-spe-
cific. The results demonstrate that the transfected miR-
34a, b, c are functional, and confirm that Bcl-2 is a direct
target of miR-34, consistent with earlier reports [8,10,16].
miR-34 restoration results in Kato III cell accumulation in 
G1 phase and caspase-3 activation
After validating that the transfected miR-34 mimics were
functional, we carried out cellular assays to examine the
effects of miR-34 restoration on gastric cancer cells. First
we evaluated the effect of miR-34 mimics on cell cycle. As
shown in Figure 6A, the miR-34 mimics induced an
accumulation of Kato III cells in G1 phase and a
reduction of cells in S phase, consistent with other reports
on miR-34 restoration in various tumor models
[4,8,10,12,13,16,17]. This effect on cell cycle is similar to
that of p53 restoration as we previously reported [18-23],
indicating that miR-34 restoration can restore p53 signal-
ling, at least in part, in the cells lacking a functional p53
pathway. Since part of the p53 tumor-suppressing func-
tion is via promoting apoptosis [19,20], we next exam-
ined the effect of miR-34 restoration on apoptosis. As
shown in Figure 6B, transient transfection of miR-34
mimics resulted in significantly increased caspase-3 acti-
vation, a key indication of the cells undergoing apoptosis.
Restoration of miR-34 by miR-34 mimic transfection down-regulates target gene Bcl-2 expressionFi re 3
Restoration of miR-34 by miR-34 mimic transfection 
downregulates target gene Bcl-2 expression. Western 
blot analysis of the potential miR-34 target protein Bcl-2 48 
hours after miR-34 mimic transfection of Kato III cells (100 
pmol per well in 6-well plates).
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qRT-PCR analysis of the relative expression levels of miR-34s and target genes in human gastric cancer cell 
lines. The cells were lyzed to extract total RNA for qRT-PCR. Data were normalized to that of Actin and the relative levels 
are shown (Actin = 1000).
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with a high level of Bcl-2
Bcl-2 is a key inhibitor of apoptosis and protects cancer
cells from apoptosis induced by chemotherapeutic agents
[24,25]. Bcl-2 is a direct target of miR-34, and our data
have shown that miR-34 restoration inhibits Bcl-2 expres-
sion. We therefore investigated whether miR-34 restora-
tion could sensitize gastric cancer cells with high a level of
Bcl-2 to chemotherapy. We chose four chemotherapeutic
agents, doxorubicin, cisplatin (CDDP), gemcitabine, and
docetaxel, all of which are used in gastrointestinal cancer
chemotherapy. As shown in Figure 7A, miR-34 restoration
in Kato III cells rendered the cells 2-3-fold more sensitive
to the four chemotherapeutic agents, as compared with
the cells transfected with the control mimic, based on
IC50 data. We have also used siRNA specific to Bcl-2 in
these cytotoxicity assays and observed a similar, 2-3-fold
chemosensitization in the Kato III cells transfected with
Bcl-2 siRNA (data not shown). However, for gastric cancer
MKN-45 cells that have a low level of Bcl-2 and a high
level of miR-34, miR-34 restoration showed no chemo-
sensitization (Figure 7B). The same results were observed
with Bcl-2 siRNA transfection (data not shown). Our data
demonstrate that miR-34 restoration can chemosensitize
those gastric cancer cells that have high levels of Bcl-2 and
low basal levels of miR-34, which are dependent on Bcl-2
for survival and drug resistance.
miR-34 restoration inhibits gastric cancer cell growth
To evaluate the long-term effects of miR-34 restoration,
we have employed a lentiviral system to express miR-34a
and have generated stable cells. Briefly, Kato III cells were
infected with the feline immunodeficiency virus (FIV) len-
tiviral system expressing miR-34a (miR-34a-MIF) or vec-
tor control (MIF), according the manufacturer's
instructions, and stable cells were obtained by antibiotic
selection (Zeocin 50 μg/mL, Invitrogen). For cell growth
analysis, the stable cells were plated in a 24-well plate
with equal cell density. Cells in triplicate were collected by
trypsinization, and viable cells were counted by Trypan
Blue exclusion at 24 hour intervals over 4 days using a
Coulter cell counter (Beckman, Fullterton, CA). As shown
Quantitative real-time PCR shows that restoration of miR-34 by miR-34 mimic transfection downregulates target gene expres-sionFigure 4
Quantitative real-time PCR shows that restoration of miR-34 by miR-34 mimic transfection downregulates 
target gene expression. 24 hours after miR-34 mimic transfection of Kato III cells (100 pmol per well in 6-well plates), 
potential target gene mRNA levels were measured by qRT-PCR with SYBR Green PCR system (TaqMan). The comparative 
threshold cycle CT method was used to calculate relative gene expression levels compared with actin, then normalized with 
the value from NC mimic as 1.
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BMC Cancer 2008, 8:266 http://www.biomedcentral.com/1471-2407/8/266in Figure 8, lentiviral restoration of miR-34a in Kato III
cells significantly delayed cell growth (P < 0.001, n = 3), a
biological activity similar to that of the p53 restoration we
reported previously [19-22].
miR-34 restoration inhibits gastric cancer tumorspheres
In our attempts to isolate gastric cancer stem cells, the
multiple cell surface markers we used did not provide
robust, tumorsphere-forming, tumor-initiating cells or
tumor stem cells. Since no cellular markers for gastric can-
cer stem cells have been widely accepted thus far, in the
current study we employed tumorsphere culture to
explore whether there is any link between miR-34 and
tumorsphere-forming cells.
Tumorsphere culture, in which cells grow in suspension
under non-adherent culture conditions to become tumor-
oid spheres, has been widely used to assess the self-
renewal potential of stem cells and cancer stem cells
[3,14,26,27]. Briefly, in our study the stable clones from
Kato III cells infected with miR-34a-MIF or control vector
MIF were plated for tumorsphere culture in ultra-low
adhesion plates. 7–10 days later, tumorspheres were
observed under a microscope and quantified. As shown in
Figure 9, restoration of miR-34 by MIF lentiviral system
inhibited Kato III tumorsphere formation and growth; the
stable cells with functional miR-34a restoration had sig-
nificantly fewer tumorspheres, and the formed tumor-
spheres were significantly smaller, as compared with that
of the MIF control (P < 0.001, Student's t-test, n = 3). This
result was confirmed by a separate tumorsphere study in a
96-well based single cell tumorsphere culture, in which
the tumorspheres were seen to be from single cells, not
from cell aggregates. Our data provide the first evidence
that miR-34 is able to inhibit tumorsphere formation and
growth in p53-mutant gastric cancer cells, implying that
miR-34 might play a role in the self-renewal of gastric can-
cer cells, presumably gastric cancer stem cells.
Restoration of miR-34 in Kato III cells resulted in G1 block and caspase-3 activationFigure 6
Restoration of miR-34 in Kato III cells resulted in G1 
block and caspase-3 activation. A. Cell cycle analysis of 
Kato III cells after miR-34 restoration. Cell cycle analysis was 
performed 24 hours after transfected with miR-34 mimics or 
negative control mimic (NC mimic). Cells were stained with 
propidium iodide after ethanol fixation and analyzed by flow 
cytometry. **P < 0.01, ***P < 0.001, versus that of NC 
mimic, one-way ANOVA, n = 2. B. Caspase-3 activation in 
Kato III cells after miR-34 restoration. 24 hours after trans-
fection, cells were lysed for measurement with the Caspase-
3 activation assay kit (BioVision). Relative increase of fluores-
cence signal was calculated by dividing the normalized signal 
in each treated sample with that of NC mimic as 100. **P < 
0.01 versus that NC mimic, two-tailed t-test, n = 3.
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Bcl-2 3'UTR Luciferase Reporter Assay shows that 
the miR-34 mimics transfected are functional. KATO3 
cells were transfected in all wells of 6-well plates with 2 ug of 
Bcl-2 3'UTR luciferase reporter plasmid or its mutant, and 2 
ug of the control β-galactosidase plasmid per well. Cells in 
each well were also co-transfected with 100 pmol of each 
miR-34 mimic or NC mimic as indicated, using Lipofectamine 
2000. Luciferase activity was normalized relative to β-gal 
activity. Data are presented as mean ± s.e. **P < 0.01, ***P < 
0.01, versus that of negative control miRNA mimic (NC 
mimic), two-tailed t-test, n = 3.
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Restoration of miR-34 chemosensitizes Kato III cells with high Bcl-2, but not MKN-45 cells with low Bcl-2Figure 7
Restoration of miR-34 chemosensitizes Kato III cells with high Bcl-2, but not MKN-45 cells with low Bcl-2. MTT-
based cytotoxicity assay of Kato III (A) and MKN-45 (B) cells transfected with miR-34a mimic or control mimic. The cells were 
transfected with miR-34a or NC mimics by Lipofectamine 2000. 24 hr later, the cells were trypsinized and plated in 96-well 
plates and treated with the indicated chemotherapeutic agents in triplicate. The MTT-based WST-1 assay was carried out on 
Day 4. Restoration of miR-34a in Kato III cells with high Bcl-2 rendered the cells 2-3-fold more sensitive to chemotherapies, 
but had no effect on MKN-45 cells with low Bcl-2. 34a, miR-34a mimic; NC, non-specific control miRNA mimic.
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Our studies demonstrate that miR-34 is involved in the
p53 tumor suppressor network; restoration of miR-34 is
able to re-establish the tumor-suppressing signalling path-
way in human gastric cancer cells lacking functional p53.
More significantly, miR-34 potently inhibits tumorsphere
formation and growth in p53-mutant human gastric can-
cer cells, providing the first proof-of-concept that there is
a potential link between the tumor suppressor miR-34
and gastric cancer cell self-renewal, which involves the
presumed gastric cancer stem cells. The mechanism of
miR-34-mediated suppression of gastric cancer cell self-
renewal might be related to the direct modulation of
downstream targets Bcl-2, Notch, and HMGA2, implying
that miR-34 may be involved in gastric cancer stem cell
self-renewal/differentiation decision-making. Our data
suggest that miR-34 may hold significant promise as a
novel molecular therapy for human gastric cancer, poten-
tially for gastric cancer stem cells.
Proteins in the Bcl-2 family are central regulators of pro-
grammed cell death, and members that inhibit apoptosis,
such as Bcl-2 and Bcl-xL, are overexpressed in many can-
cers and contribute to tumor initiation, progression, and
resistance to therapy [28]. Bcl-2 is the founding member
of this family of proteins and was first isolated as the
product of an oncogene [29,30]. This family of proteins
includes both anti-apoptotic molecules, such as Bcl-2 and
Bcl-xL, and pro-apoptotic molecules such as Bax, Bak, Bid,
and Bad [31]. These are crucial regulators of apoptosis
mediated by the Bcl-2 family of proteins [29,32,33]. Over-
expression of Bcl-2 is observed in a majority of human
cancers, including gastric cancer [34]. The expression level
of Bcl-2 protein also correlates with resistance to a wide
spectrum of chemotherapeutic agents and radiation ther-
apy [30,35-37]. Overexpression of Bcl-2 protein decreases
the pro-apoptotic response to such cellular insults as irra-
diation and chemotherapy, leading to resistance to the
treatments [38-40]. Thus, Bcl-2 is a highly attractive target
for the development of novel molecular therapy for the
treatment of human cancer.
In our recent study with multidrug resistant human gastric
cancer AGS cells, Bcl-2 upregulation and p53 downregula-
tion are found to be involved in drug resistance [34].
Thus, simultaneous inhibition of Bcl-2 function and res-
toration of p53 represents a promising strategy to over-
come drug resistance and improve efficacy for the
treatment of p53-mutant gastric cancer. This strategy was
explored in the current study, where p53 downstream tar-
get miR-34 was restored in p53-mutant gastric cancer Kato
III cells with a high level of Bcl-2 and low levels of miR-
34, resulting in downregulation of Bcl-2 and Notch/
HMGA2, tumor cell growth inhibition and accumulation
in G1 phase, and chemosensitization and Caspase-3 acti-
vation/apoptosis. miR-34 restoration could thus rebuild,
at least in part, the p53 tumor-suppressing signalling net-
work in gastric cancer cells lacking p53 function. This
multi-mode action of miR-34 provides a therapeutic
advantage over other molecular therapies, in that miR-34
has multiple targets and can work on multiple cell signal-
ling pathways simultaneously, leading to synergistic
effects that may translate into improved clinical efficacy
for gastric cancer patients with p53 deficiency and multi-
drug resistance.
Another important implication from the current study is
that our data provide a potential link between tumor sup-
pressor miR-34 and the presumed gastric cancer stem
cells. Cancer stem cells are a small subpopulation of cells
capable of self-renewal and differentiation, and have been
identified in a variety of tumors [14,41-45]. Cancer stem
cells are believed to be responsible for tumor initiation,
progression, metastasis, and resistance to therapy [26,46-
49]. To be maximally effective, cancer therapy must be
directed against both the resting cancer stem cells and the
proliferating cancer cells [47]. This may be possible if spe-
cific stem cell signals are inhibited using molecular ther-
apy, while at the same time proliferating cells are attacked
Restoration of miR-34 in Kato III cells delays cell growthFigure 8
Restoration of miR-34 in Kato III cells delays cell 
growth. Kato III cells were infected with feline immunodefi-
ciency virus (FIV) lentiviral system expressing miR-34a (miR-
34a-MIF) or vector control (MIF), and stable cells were 
obtained by antibiotic selection (Zeocin 50 μg/mL) and vali-
dated for miR-34a expression. The stable cells were plated in 
a 24-well plate with equal cell density. Cells in triplicate were 
collected by trypsinization and viable cells were counted by 
Trypan Blue exclusion at 24-h intervals over 4 days, using a 
Coulter cell counter (Beckman). ***P < 0.001 versus MIF 
vector control, two-way ANOVA, n = 3.
0 1 2 3 4
0
10
20
30
40 miR34a-MIF
MIF
***p<0.001
Days
C
e
lls
 / 
w
e
ll 
(X
 
10
4 )Page 9 of 12
(page number not for citation purposes)
BMC Cancer 2008, 8:266 http://www.biomedcentral.com/1471-2407/8/266by conventional therapies [48,50]. There are limited stud-
ies of gastric cancer stem cells, and thus far there are no
suitable, widely accepted cellular markers for these rare
cells [51,52]. Stem cells are defined by their ability to
undergo self-renewal, as well as by multi-lineage differen-
tiation [53]. In our attempts to isolate gastric cancer stem
cells, the multiple cell surface markers we used in gastric
cancer cell lines did not provide robust, tumorsphere-
forming, tumor-initiating cells or cancer stem cells. This
might be due to the use of incorrect markers, or the fact
that primary tumor tissues should have been examined
instead of the established cell lines. However, our data
indicate that miR-34 restoration inhibits tumorspheres
from p53-mutant gastric cancer cells, suggesting that miR-
34 might be involved in the self-renewal of the presumed
gastric cancer stem cells. In a separate project on pancre-
atic and prostate cancer stem cells, our preliminary data
indicate that miR-34s are indeed involved in these cancer
stem cells, supporting our hypothesis (Ji et al., manuscript
submitted). Currently, we are testing a series of cellular
markers for human gastric cancer stem cells (CD44,
CD24, CD133, ESA, ALDH1, etc.) and using human pri-
mary gastric cancer tissues to identify the true side popu-
lation of the assumed gastric cancer stem cells, and to
delineate the role of miR-34 in these tumor-initiating
cells.
Conclusion
Our results demonstrate that in p53-deficient human gas-
tric cancer cells, restoration of functional microRNA miR-
34 inhibits cell growth, induces apoptosis, and leads to
chemosensitization, indicating that miR-34 may restore,
Restoration of miR-34 by MIF lentiviral system inhibits Kato III tumorspheresFigure 9
Restoration of miR-34 by MIF lentiviral system inhibits Kato III tumorspheres. Kato III cells infected by miR-34a MIF 
or control vector MIF were plated for tumorsphere formation as described in Materials and Methods. 7–10 days later, tumor-
spheres were observed under microscope (A) and quantified (B). C. Quantification of cell numbers per tumorsphere. Tumor-
spheres were collected and filtered through a 40 um sieve (BD Biosciences), and dissociated with trypsin for single cell 
suspension. Cells were counted with trypan blue exclusion and the data are presented as number of cells per tumorsphere. **P 
< 0.01, Student's t-test, n = 3.
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BMC Cancer 2008, 8:266 http://www.biomedcentral.com/1471-2407/8/266at least in part, the p53 tumor-suppressing function. miR-
34 restoration inhibits tumorsphere formation and
growth, which is reported to be correlated to the self-
renewal of cancer stem cells. The mechanism of miR-34-
mediated suppression of self-renewal might be related to
the direct modulation of downstream targets Bcl-2,
Notch, and HMGA2, indicating that miR-34 may be
involved in gastric cancer stem cell self-renewal/differenti-
ation decision-making. Our study suggests that restora-
tion of the tumor-suppressor miR-34 may provide a novel
molecular therapy for p53-mutant gastric cancer.
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